Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSEY IPSEN	$31.25 +2.3%	$29.65	$25.11 ▼ $32.25	$10.24B	0.53	743 shs	191 shs
ONC BeOne Medicines	$290.35 +4.0%	$249.71	$148.81 ▼ $298.00	$30.60B	0.28	315,581 shs	804,900 shs
SDZNY Sandoz Group	$56.00 -1.0%	$51.85	$35.61 ▼ $57.07	$24.89B	0.6	19,817 shs	21,389 shs
SMMT Summit Therapeutics	$27.63 -2.3%	$22.77	$8.71 ▼ $36.91	$21.00B	-1.01	3.75 million shs	3.08 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSEY IPSEN	+2.32%	+1.73%	+3.80%	+21.27%	+2.86%
ONC BeOne Medicines	+4.01%	+14.59%	+14.27%	+25.70%	+29,034,999,900.00%
SDZNY Sandoz Group	-0.97%	0.00%	+7.71%	+39.17%	+43.85%
SMMT Summit Therapeutics	-2.26%	+6.76%	+39.19%	+12.27%	+196.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPSEY IPSEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	2.5442 of 5 stars	3.5	0.0	0.0	0.0	3.0	1.7	0.6
SDZNY Sandoz Group	1.7233 of 5 stars	0.0	5.0	0.8	0.0	0.0	0.0	2.5
SMMT Summit Therapeutics	2.8746 of 5 stars	4.4	3.0	0.0	0.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSEY IPSEN	3.00	Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$327.56	12.81% Upside
SDZNY Sandoz Group	2.00	Hold	N/A	N/A
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	25.47% Upside

Current Analyst Ratings Breakdown

Latest IPSEY, ONC, SDZNY, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/8/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSEY IPSEN	$3.87B	2.71	N/A	N/A	N/A	∞
ONC BeOne Medicines	$3.81B	8.35	N/A	N/A	$34.10 per share	8.51
SDZNY Sandoz Group	$10.36B	2.38	$2.65 per share	21.16	$18.56 per share	3.02
SMMT Summit Therapeutics	$700K	29,314.25	N/A	N/A	$0.53 per share	52.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSEY IPSEN	$374.30M	N/A	0.00	10.85	N/A	N/A	N/A	N/A	7/31/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	408.94	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)
SDZNY Sandoz Group	$1M	N/A	0.00	16.87	0.98	N/A	N/A	N/A	8/7/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)

Latest IPSEY, ONC, SDZNY, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSEY IPSEN	$0.26	0.83%	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SDZNY Sandoz Group	$0.44	0.79%	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest IPSEY, ONC, SDZNY, and SMMT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/3/2025	IPSEY IPSEN		$0.2896	0.97%	6/9/2025	6/10/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSEY IPSEN	N/A	1.34	1.15
ONC BeOne Medicines	0.05	1.96	1.71
SDZNY Sandoz Group	0.57	1.24	0.79
SMMT Summit Therapeutics	N/A	10.63	10.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSEY IPSEN	N/A
ONC BeOne Medicines	48.55%
SDZNY Sandoz Group	0.06%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
IPSEY IPSEN	N/A
ONC BeOne Medicines	6.62%
SDZNY Sandoz Group	N/A
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSEY IPSEN	5,358	335.26 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable

IPSEY, ONC, SDZNY, and SMMT Headlines

Recent News About These Companies

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 17 at 10:53 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 17 at 10:00 AM | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?

July 16 at 1:00 PM | marketbeat.com

Florida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)

July 15 at 5:50 AM | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 12, 2025 | prnewswire.com

12,025 Shares in Summit Therapeutics PLC (NASDAQ:SMMT) Purchased by U.S. Capital Wealth Advisors LLC

July 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (SMMT) Stock Price Today - WSJ

July 10, 2025 | wsj.com

Summit Therapeutics (NASDAQ:SMMT) Trading 7.6% Higher - Here's Why

July 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 7, 2025 | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why

July 7, 2025 | marketbeat.com

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

July 7, 2025 | zacks.com

Summit Therapeutics Inc. (SMMT) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

2 Soaring Stocks With More Upside Potential to Buy and Hold

July 4, 2025 | fool.com

AstraZeneca in talks with Summit for over $15 billion license deal

July 4, 2025 | thepharmaletter.comT

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

July 3, 2025 | msn.com

Summit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZeneca

July 3, 2025 | msn.com

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

July 3, 2025 | msn.com

Why Summit Therapeutics Stock Soared 8% Higher Today

July 3, 2025 | fool.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?

July 3, 2025 | marketbeat.com

Summit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT)

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
These 3 Dividend Stocks Are Not Concerned With Tariff Noise
By Thomas Hughes | July 11, 2025
View These 3 Dividend Stocks Are Not Concerned With Tariff Noise
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders
MarketBeat Week in Review – 07/07 - 07/11
By MarketBeat Staff | July 12, 2025
View MarketBeat Week in Review – 07/07 - 07/11

IPSEY, ONC, SDZNY, and SMMT Company Descriptions

IPSEN OTCMKTS:IPSEY

$31.25 +0.71 (+2.32%)

As of 07/17/2025 12:29 PM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

BeOne Medicines NASDAQ:ONC

$290.35 +11.19 (+4.01%)

As of 07/17/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Sandoz Group OTCMKTS:SDZNY

$56.00 -0.56 (-0.99%)

As of 07/17/2025 03:59 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Summit Therapeutics NASDAQ:SMMT

$27.63 -0.64 (-2.26%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$27.66 +0.04 (+0.13%)

As of 07/17/2025 07:53 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time